139 related articles for article (PubMed ID: 3367673)
1. Flutamide--an antiandrogen inhibiting prostatic cancer and prostatic secretion with retention of potency.
Stegmayr B; Johansson JE; Schnürer LB
Med Oncol Tumor Pharmacother; 1988; 5(1):61-5. PubMed ID: 3367673
[TBL] [Abstract][Full Text] [Related]
2. Experience with flutamide in previously untreated patients with advanced prostatic cancer.
Sogani PC; Whitmore WF
J Urol; 1979 Nov; 122(5):640-3. PubMed ID: 501817
[TBL] [Abstract][Full Text] [Related]
3. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy.
Sogani PC; Vagaiwala MR; Whitmore WF
Cancer; 1984 Aug; 54(4):744-50. PubMed ID: 6378356
[TBL] [Abstract][Full Text] [Related]
4. Flutamide as primary treatment for metastatic prostatic cancer.
Lundgren R
Br J Urol; 1987 Feb; 59(2):156-8. PubMed ID: 3828712
[TBL] [Abstract][Full Text] [Related]
5. Long-term experience with flutamide in patients with prostatic carcinoma.
Prout GR; Keating MA; Griffin PP; Schiff SF
Urology; 1989 Oct; 34(4 Suppl):37-45; discussion 46-56. PubMed ID: 2800092
[TBL] [Abstract][Full Text] [Related]
6. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study.
Têtu B; Srigley JR; Boivin JC; Dupont A; Monfette G; Pinault S; Labrie F
Am J Surg Pathol; 1991 Feb; 15(2):111-20. PubMed ID: 1989458
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate.
Johansson JE; Andersson SO; Beckman KW; Lingårdh G; Zador G
Urology; 1987 Jan; 29(1):55-9. PubMed ID: 3798631
[TBL] [Abstract][Full Text] [Related]
8. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
St Arnaud R; Lachance R; Dupont A; Labrie F
J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
[TBL] [Abstract][Full Text] [Related]
9. Flutamide therapy for advanced prostatic cancer: a phase II study.
MacFarlane JR; Tolley DA
Br J Urol; 1985 Apr; 57(2):172-4. PubMed ID: 3986452
[TBL] [Abstract][Full Text] [Related]
10. Advanced prostatic carcinoma: flutamide therapy after conventional endocrine treatment.
Sogani PC; Ray B; Whitmore WF
Urology; 1975 Aug; 6(2):164-6. PubMed ID: 1145932
[TBL] [Abstract][Full Text] [Related]
11. [Lack of effect of therapy with LHRH analogs, alone or associated with flutamide, on prolactin levels in advanced prostatic carcinoma].
Banchini A; Zavaroni D; Tarditi E; Cortellini P; Ziveri M; Polotti R; Stefani F; Valenti G
Minerva Endocrinol; 1989; 14(3):165-8. PubMed ID: 2533662
[TBL] [Abstract][Full Text] [Related]
12. Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer.
Jacobo E; Schmidt JD; Weinstein SH; Flocks RH
Urology; 1976 Sep; 8(3):231-3. PubMed ID: 788293
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with flutamide and castration: its benefits at various stages of prostate cancer.
Labrie F; Dupont A; Cusan L; Manhès G; Bergeron N; Lacourcière Y; Pineault S; Bélanger A; Monfette G; Emond J
Prog Clin Biol Res; 1989; 303():161-7. PubMed ID: 2674982
[No Abstract] [Full Text] [Related]
14. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
16. A new antiprostatic agent for treatment of prostatic carcinoma.
Irwin RJ; Prout GR
Surg Forum; 1973; 24():536-7. PubMed ID: 4806089
[No Abstract] [Full Text] [Related]
17. [Use of flutamide in the treatment of carcinoma of the prostate stages C and D (T3-T4, Nx-N0, M0-M1 categories)].
Daricello G; Caramia G; Rizzo FP; Serretta V; Di Trapani D; Pavone-Macaluso M
Minerva Urol Nefrol; 1986; 38(1):71-6. PubMed ID: 3738681
[No Abstract] [Full Text] [Related]
18. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Chen Y; Kolvenbag GJ
Cancer; 1996 Nov; 78(10):2164-9. PubMed ID: 8918410
[TBL] [Abstract][Full Text] [Related]
19. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.
Brufsky A; Fontaine-Rothe P; Berlane K; Rieker P; Jiroutek M; Kaplan I; Kaufman D; Kantoff P
Urology; 1997 Jun; 49(6):913-20. PubMed ID: 9187700
[TBL] [Abstract][Full Text] [Related]
20. Flutamide: an antiandrogen for advanced prostate cancer.
Goldspiel BR; Kohler DR
DICP; 1990 Jun; 24(6):616-23. PubMed ID: 2193461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
